Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019)

Jaguar Health (JAGX) reported Non-Current Deferred Tax Liability of $20594.0 for Q4 2019, down 97.92% quarter-over-quarter from $990549.0 in Q3 2017.

Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019) Analysis & Trends

Jaguar Health (JAGX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $20594.0 in Q4 2019.

Non-Current Deferred Tax Liability for Q4 2019 came in at $20594.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $20594.0 (changed N/A YoY), and the FY2019 annual result was $20594.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability declined to $20594.0 in Q4 2019 per JAGX's latest filing, from $990549.0 in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $990549.0 in Q3 2017 and troughed at $20594.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Jaguar Health	1.44 Mn	-10.19 Mn	19.11 Mn

Download Data